Your shopping cart is currently empty

ZYF0033 is an orally effective small molecule inhibitor of hematopoietic progenitor kinase 1 (HPK1) that inhibits the phosphorylation of MBP proteins.HPK1-IN-22 promotes anticancer immune responses by decreasing the phosphorylation of SLP76 (serine 76), and has the potential to inhibit tumor growth and mediate immune responses.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $142 | In Stock | In Stock | |
| 5 mg | $266 | In Stock | In Stock | |
| 10 mg | $453 | - | In Stock | |
| 25 mg | $955 | - | In Stock | |
| 50 mg | $1,620 | - | In Stock |
| Description | ZYF0033 is an orally effective small molecule inhibitor of hematopoietic progenitor kinase 1 (HPK1) that inhibits the phosphorylation of MBP proteins.HPK1-IN-22 promotes anticancer immune responses by decreasing the phosphorylation of SLP76 (serine 76), and has the potential to inhibit tumor growth and mediate immune responses. |
| In vitro | ZYF0033 (HPK1-IN-22) (100 nM, 24 h) reduces the phosphorylation of SLP76 (serine 376) in T cells, leading to HPK1 inhibition and increasing the proliferation of CD4+ and CD8+ T cells and the secretion of IFN-γ. [1] |
| Synonyms | ZYF 0033, HPK1-IN-22 |
| Molecular Weight | 462.61 |
| Formula | C26H30N4O2S |
| Cas No. | 2380300-79-6 |
| Smiles | OC(C#CC1=CC=CC(=C1)COC=2C=C(C=NC2N)C=3SC(=NC3)C4CCN(C)CC4)(C)C |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (172.93 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (7.13 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.